Immune checkpoint inhibitors (ICI) are commonly associated with thyroid immune-related adverse events, yet the mechanism has not been fully elucidated. We aimed to further explore the mechanism of ICI-induced thyroid dysfunction by assessing changes induced in the thyroid transcriptome by ICI treatment (αPD-1/αPD-L1) in a lung cancer murine model. RNA-sequencing of thyroid tissues revealed 952 differentially expressed genes (DEGs) with αPD-1 treatment (|fold-change| ≥1.8, FDR < 0.05). Only 35 DEG were identified with αPD-L1, and we therefore focused on the αPD-1 group alone. Ingenuity Pathway Analysis revealed that of 952 DEGs with αPD-1 treatment, 362 were associated with functions of cell death and survival, with predicated activation of pathways for apoptosis and necrosis (Z = 2.89 and Z = 3.21, respectively) and negative activation of pathways for cell viability and cell survival (Z = −6.22 and Z = −6.45, respectively). Compared to previously published datasets of interleukin-1β and interferon γ-treated human thyroid cells, apoptosis pathways were similarly activated. However, unique changes related to organ inflammation and upstream regulation by cytokines were observed. Our data suggest that there are unique changes in gene expression in the thyroid associated with αPD-1 therapy. ICI-induced thyroid dysfunction may be mediated by increased tissue apoptosis resulting in destructive thyroiditis.
Objectives: This study aimed to describe the clinical, optical coherence tomography (OCT) and OCT angiography (OCTA) findings and characteristics in patients with perifoveal exudative vascular anomalous complex (PEVAC) and compare the macular vascular density with the age-matched control group. Methods: We conducted a case–control study to compare demographic information, clinical observations, and OCT/OCTA findings in eyes with PEVAC (n = 5 eyes in 5 patients) and a control group of subjects matched for age (n = 9). The Advanced Retina Imaging (ARI) network algorithms were utilized to evaluate OCTA observations. Statistical analysis was performed by the nonparametric Mann–Whitney U test. Results: Patients with PEVAC had a mean (±SD) age at presentation of 70 ± 12.6 years, the mean follow-up period was 7.8 ± 5.2 months, and unilateral disease was observed. Four out of the five patients in our cohort had a history of systemically treated hypertension and dyslipidemia. Three eyes had lesions in the inner temporal retinal zone, while the remaining two eyes had lesions in the inner inferior or central zone. Retina slab analysis using OCTA showed no significant difference in vascular density parameters between the PEVAC and control groups. Conclusions: Although limited by a small sample size, our study suggests that macular vessel density shows no significant difference between PEVAC cases and control eyes.
Purpose: Cutaneous melanoma (CM) and uveal melanoma (UM) derive from melanocytes. Nevertheless, they differ in genetic drivers and progression pathways. Previous research examining the relationship between CM and UM has been constrained by small cohorts and the rarity of UM. The aim of this study was to determine whether UM occurs more frequently in patients with a CM compared to matched patients with keratinocyte carcinoma (KC, squamous or basal cell carcinoma of the skin). Patients with KC were selected as the control to account for the excess risk due to sun exposure and access to healthcare. Methods: We performed a large, multicenter retrospective cohort study using TriNetX, a global health research network and real-world data platform. Cohort 1 had CM or melanoma in situ (MIS) and no history of KC. Cohort 2 had KC and no history of CM or MIS. The main outcome was the incidence of malignant neoplasms of the choroid or ciliary body over a 5-year follow-up, including diagnoses recorded before the index skin cancer. Patients who had metastatic disease were excluded to remove potential misidentifications of choroidal metastasis as UM. A 1:1 propensity score matching (PSM) was used to match demographic and clinical characteristics. Odds ratios (ORs) with 95% confidence intervals (CIs) and corresponding two-sided p-values were used to compare categorical outcomes. Ophthalmologic follow-up was evaluated to rule out surveillance bias. Results: The CM cohort included 57,352 patients. The KC cohort included 137,083 patients. After PSM each cohort included 52,860 patients. UM occurred in 53 CM patients (0.1%) compared with 13 KC patients (0.02%). This corresponds to an OR of 4.08 (95% CI [2.22, 7.49]; p < 0.001). UM diagnosis preceded CM in 70% of patients with both diagnoses. The association persisted in a sensitivity analysis after excluding patients with UM documented before CM (HR 14.32; 95% CI 7.96–25.76). Conclusions: Cutaneous melanoma is associated with a significantly higher risk of UM compared to KC. These findings suggest a link between cutaneous and uveal melanoma and may offer a possible role for ophthalmic surveillance in CM patients and dermatology surveillance in UM patients.
18 August 2026 in International Journal of Retina and Vitreous
Background: Cigarette smoking is a well-established risk factor for age-related macular degeneration (AMD), but the relationship between nicotine-related exposures recorded in electronic health records and AMD remains unclear. We evaluated whether documented non-tobacco nicotine dependence (NTND) coding was associated with incident AMD. Methods: In this retrospective cohort study using the TriNetX Global Collaborative Network, adults aged ≥ 50 years with documented NTND were compared with individuals without documented nicotine dependence after exclusion of patients with recorded tobacco use. Propensity score matching (1:1) was performed to balance demographic characteristics, systemic comorbidities, ophthalmic conditions, healthcare utilization, and medication exposures. Primary outcomes were incident non-neovascular AMD and neovascular AMD over up to 10 years of follow-up. Sensitivity analyses included restriction to patients who survived the study period, five- and seven-year follow-up, and a landmark analysis indexed at the second qualifying event. Results: After matching, 37,411 patients were included in each cohort. Documented NTND coding was associated with higher incidence of non-neovascular AMD (non-nvAMD; 1.74% vs. 0.92%; hazard ratio [HR] 1.50, 95% confidence interval [CI] 1.31–1.71; E-value 2.37) and neovascular AMD (nvAMD; 0.78% vs. 0.36%; HR 1.69, 95% CI 1.37–2.07; E-value 2.77). NvAMD remained significantly associated in the survivor-restricted, five-year, seven-year, and landmark analyses, whereas non-nvAMD remained significant only in the survivor-restricted analysis. The NTND cohort also demonstrated substantially higher risks of chronic obstructive pulmonary disease (HR 5.65, 95% CI 5.14–6.20; E-value 10.78) and lung cancer (HR 5.74, 95% CI 4.77–6.91; E-value 10.96). Conclusions: Documented NTND coding was associated with increased AMD incidence in the primary analysis, with a more consistent association for nvAMD across sensitivity analyses. However, the exposure definition likely includes a heterogeneous population and may reflect a combination of nicotine-related exposures and incompletely captured prior cigarette smoking. These findings should therefore be considered hypothesis-generating and underscore the challenges of studying nicotine-related exposures using standardized clinical data.